Jaypirca (pirtobrutinib) — Highmark
Relapsed or Refractory Mantle Cell Lymphoma (MCL)
Initial criteria
- age ≥ 18 years
- diagnosis of relapsed or refractory MCL (ICD-10 C83.1)
- received at least two prior lines of systemic therapy, including at least one BTK inhibitor